Prize for animal-free antibodies
by the European Coalition to End Animal Experiments
The aim of this prize is to highlight the versatility and superiority of animal-free antibodies and encourage their acceptance and use for research and therapeutic purposes.
Altertox Academy: The Podcast
by Jeanne Laperrouze
Vera Rogiers, Emeritus Professor of Toxicology and Chair of the Innovation Centre – 3Rs at the Vrije Universiteit Brussel, explains the creation and actions of the Centre to promote the implementation of the 3Rs in scientific research by using new technology and new approach methodologies (NAMs). She describes the peculiar situation of Belgium, a federal state, when it comes to promoting NAMs and also discusses the upcoming revision of the REACH Regulation and what can be expected from the EU Green Deal.
Blog on the where we are with the use of laboratory animals and alternatives
by Mieke Van Mulders in EOS Science
If scientists could stop animal testing, they would do it immediately. But is it feasible? How far is science today?
Ray Tice Tox21 Student Award for Anouck Thienpont
by The American Society for Cellular and Computational Toxicology (ASCCT)
The American Society for Cellular and Computational Toxicology (ASCCT) recently organized its 10th annual meeting themed “Practical applications of new tools in toxicology” from the 12th to the 14th of October.
During the meeting, Anouck Thienpont from Sciensano and the Vrije Universiteit Brussel received the Ray Tice Tox21 Student Award for her presentation ‘Development of a novel #genotoxicity prediction model based on #biomarkergenes in human HepaRGTM cells’.
This prediction model allows to predict the genotoxic potential of chemicals based on the changes in the expression of 84 carefully selected genes. The work is part of a joint PhD project between VUB and Sciensano, funded by the FWO and the Chair Mireille Aerens.
UK biotech body creates new strategic goals for investment in research
By Nick Taylor in biopharma-reporter.com
A UK body that provides £75m (€88m) a year for research into biotechnology and biological sciences has changed its approach to investment.